Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2022-08-30 Director's Dealing
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: Thông báo giao dịch cổ phiếu của Người nội bộ Trần Thị Đào
Director's Dealing Classification · 93% confidence The document is a formal notice of insider transactions by a company director (the Vice Chairman/CEO), detailing share/fund certificate holdings before and after trades, transaction quantities, purpose, and methods. This fits the definition of Director's Dealing filings, reporting personal share transactions by company insiders.
2022-08-30 Vietnamese
IMP: Thông báo chào mua công khai IMP của SK
M&A Activity Classification · 95% confidence The document is a formal public tender offer notice (“Chào Mua Công Khai”) filed with the Ho Chi Minh Stock Exchange, detailing offer price, quantity, timeline, target shareholding, financing, and conditions for a takeover bid. This clearly constitutes an announcement of a takeover bid M&A activity rather than an annual or interim report, management change, or other category.
2022-08-22 Vietnamese
IMP: Nghị quyết và Biên bản họp HĐQT về việc phê duyệt ý kiến đối với việc chào mua công khai SK
M&A Activity Classification · 85% confidence The document is an official disclosure made to the State Securities Commission and Ho Chi Minh Stock Exchange by Imexpharm. It attaches and publishes Board of Directors’ minutes and resolutions approving SK Investment Vina III Pte. Ltd.’s public tender offer for Imexpharm shares. This is clearly a takeover offer announcement with related board materials, fitting the “M&A Activity” category for takeover bid filings (Code: TAR).
2022-08-17 Vietnamese
IMP: Thông báo nhận được Hồ sơ chào mua công khai từ SK
M&A Activity Classification · 93% confidence The document is a formal public disclosure by Imexpharm to the State Securities Commission and Ho Chi Minh Stock Exchange regarding a public takeover offer (“chào mua công khai”) by a related party to increase its shareholding from 53.94% to 55.04%. This is clearly an announcement of a tender offer, fitting the definition of M&A Activity (Code: TAR) for takeover bids, not merely a share issue or major shareholding threshold notification. The document includes detailed terms of the offer (quantity, price, intermediary), making TAR the most appropriate classification.
2022-08-16 Vietnamese
IMP: Nghị quyết HĐQT về việc phê duyệt ý kiến đối với việc chào mua công khai cổ phiếu IMP
M&A Activity Classification · 85% confidence The document is a formal disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange containing the full text of the Imexpharm Board of Directors’ Resolution No. 08/NQ-HĐQT-IMP dated July 27, 2022, which approves the company’s response to a public tender offer of its shares by SK Investment Vina III Pte. Ltd. This is clearly related to a takeover bid and thus falls under M&A activity disclosures, not merely a management change or routine report. Therefore, it should be classified as M&A Activity.
2022-07-28 Vietnamese
IMP: Nghị quyết HĐQT sô 07 ngày 27/07/2022
Board/Management Information Classification · 85% confidence The document is a Board of Directors resolution (Nghị quyết HĐQT) of Imexpharm disclosed on the State Securities Commission and Ho Chi Minh Stock Exchange portals. It contains the full text of the board’s meeting resolution, including approvals for Q2 results, funding decisions, strategic share auction participation, and appointments of representatives to another company’s board. This is a corporate board announcement rather than a financial report, earnings release, or other regulatory filing. Therefore, it should be classified as Board/Management Information (MANG).
2022-07-28 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.